nach oben

Die Pathologie

Erschienen in:

31.10.2016 | Hauptreferate: Hämatopathologie

Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms

verfasst von: A. Mullally, MD

Erschienen in: Die Pathologie | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Chronic myeloproliferative neoplasms (MPN) comprise a spectrum of clonal neoplastic disorders characterized by overproduction of terminally differentiated cells of the myeloid lineage. A common genetic basis for the BCR-ABL-negative MPN disorders was elucidated in 2005 with the identification of the JAK2V617F mutation in the majority of MPN patients. The discovery of JAK2V617F had a dramatic impact on the diagnosis and treatment of MPN. Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis. The drug is now also approved in Europe and Canada.

Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061CrossRefPubMed

James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148CrossRefPubMed

Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790CrossRefPubMed

Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397CrossRefPubMed

Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6(4):372–375PubMed

Prchal JF, Axelrad AA (1974) Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 290(24):1382PubMed

Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459–468CrossRefPubMedPubMedCentral

Ma W, Kantarjian H, Zhang X et al (2009) Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 11(1):49–53CrossRefPubMedPubMedCentral

Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 19(8):754–759CrossRefPubMedPubMedCentral

10.

Toms AV, Deshpande A, McNally R et al (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol 20(10):1221–1223CrossRefPubMedPubMedCentral

11.

Ungureanu D, Wu J, Pekkala T et al (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 18(9):971–976CrossRefPubMedPubMedCentral

12.

Walz C, Ahmed W, Lazarides K et al (2012) Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 119(15):3550–3560CrossRefPubMedPubMedCentral

13.

Yan D, Hutchison RE, Mohi G (2012) Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 119(15):3539–3549CrossRefPubMedPubMedCentral

14.

Kralovics R, Guan Y, Prchal JT (2002) Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30(3):229–236CrossRefPubMed

15.

Jamieson CH, Gotlib J, Durocher JA et al (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 103(16):6224–6229CrossRefPubMedPubMedCentral

16.

Ishii T, Bruno E, Hoffman R, Xu M (2006) Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108(9):3128–3134CrossRefPubMed

17.

Delhommeau F, Dupont S, Tonetti C et al (2007) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109(1):71–77CrossRefPubMed

18.

Anand S, Stedham F, Beer P et al (2011) Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 118(1):177–181CrossRefPubMed

19.

Stein BL, Williams DM, Rogers O, Isaacs MA, Spivak JL, Moliterno AR (2011) Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol 39(1):95–101CrossRefPubMed

20.

Xu X, Zhang Q, Luo J et al (2007) JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 109(1):339–342CrossRefPubMedPubMedCentral

21.

Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96(3):450–453CrossRefPubMed

22.

Dupont S, Masse A, James C et al (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110(3):1013–1021CrossRefPubMed

23.

Gale RE, Allen AJ, Nash MJ, Linch DC (2007) Long-term serial analysis of X‑chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 109(3):1241–1243CrossRefPubMed

24.

Godfrey AL, Chen E, Pagano F et al (2012) JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 120(13):2704–2707CrossRefPubMedPubMedCentral

25.

Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C (1991) Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 85(3):124–127CrossRefPubMed

26.

Campbell PJ, Baxter EJ, Beer PA et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108(10):3548–3555CrossRefPubMed

27.

Theocharides A, Boissinot M, Girodon F et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1):375–379CrossRefPubMed

28.

Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798CrossRefPubMed

29.

Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807CrossRefPubMedPubMedCentral

30.

Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S (2015) The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 126(13):1551–1554CrossRefPubMedPubMedCentral

31.

Cervantes F, Vannucchi AM, Kiladjian JJ et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047–4053CrossRefPubMed

32.

Pardanani A, Laborde RR, Lasho TL et al (2013) Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27(6):1322–1327CrossRefPubMedPubMedCentral

Titel: Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms
verfasst von: A. Mullally, MD
Publikationsdatum: 31.10.2016
Verlag: Springer Medizin
Erschienen in: Die Pathologie / Ausgabe Sonderheft 2/2016
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-016-0240-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2016

Neue prognostische und prädiktive Marker beim Mammakarzinom

Eröffnungsrede der Tagungspräsidentin der Deutschen Gesellschaft für Pathologie

Prädiktive molekularpathologische Stratifizierung hämatologischer Neoplasien

Bericht der AG Kinder- und Fetalpathologie

Bericht über die Sitzung der AG Hämatopathologie

Jochen Kunz

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin